Table 1.

Patients^* Characteristics

Variable (n=81)	N (%)
Age at transplant	Median 35 years (range 6–66)
Gender
Male	47(58)
Female	34 (42)
Disease distribution
AML/MDS	25 (30.8)
ALL	3 (3.7)
CML	49 (60.5)
Others	4 (4.9)
Stem cell source
BMT	15 (18.5)
PBSCT	66 (81.5)
Conditioning regimen
MST	72 (90)
RIC	9 (10)
Acute GVHD (grades)
I–IV	35 (43.2)
II–IV	15 (18.5)
Chronic GVHD	66 (81.5) [L50; E 16]
Prolonged IST (> 3 year)	14 (17)
Mortality beyond 3 year follow up	2 (2.5)
Hypothyroidism (time to hypothyroidism-median, range)
All cases (28 mo, 3–78)	30 (37)
Subclinical (20 mo, 3–38)	21 (25.9)
Overt (32 mo, 9–78)	9 (11.1)
Total no of patients on treatment	20 (24.7)
Positive anti-thyroid antibodies (n=60)	12 (20)

^*Follow-up period, median 84 mo (range 25–166); AML-acute myeloid leukemia, ALL-acute lymphoblastic leukemia, CML-chronic myeloid leukemia, L-limited; E-extensive; MST-TBI based myeloablative conditioning; RIC-reduced intensity conditioning; IST-immunosuppressive therapy, mo-months